GlassScriptPhysician profile
Jason M Leonard
NPI 1033290093
$12,225.54
in general payments reported to CMS, 2019-2025
49 companies · $837 in 2025
The $837 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $856 · 2020: $756 · 2021: $2,719 · 2022: $4,214 · 2023: $1,814 · 2024: $1,030 · 2025: $837.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,581 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,580.78 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $100.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,788.17 | 2022-2025 | Linq II, Micra, Azure Xt Dr Mri Surescan |
| Astrazeneca Pharmaceuticals LP | $2,165.65 | 2019-2023 | Farxiga, Evusheld |
| Abbvie INC. | $855.92 | 2020-2023 | |
| Janssen Pharmaceuticals, INC | $795.95 | 2019-2023 | Xarelto |
| Lilly USA, LLC | $726.74 | 2020-2023 | Mounjaro, Trulicity |
| Glaxosmithkline, LLC. | $557.15 | 2019-2023 | Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $455.47 | 2019-2023 | Xifaxan |
| Novo Nordisk INC | $410.73 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $270.31 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $257.01 | 2019-2023 | Jardiance |
| Abbott Laboratories | $241.08 | 2021-2023 | Freestyle Libre 3, Freestyle Libre 2 |
| Corcept Therapeutics | $231.22 | 2021-2023 | Korlym |
| Novartis Pharmaceuticals Corporation | $227.19 | 2019-2023 | |
| Insulet Corporation | $222.72 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $203.08 | 2022-2023 | Rexulti |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Leonard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.